Welcome to our dedicated page for Virios Therapeutics SEC filings (Ticker: VIRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VIRI SEC filings page on Stock Titan serves as an access point to the regulatory history of Virios Therapeutics, Inc. and its successor, Dogwood Therapeutics, Inc. Virios Therapeutics previously reported as a development-stage biotechnology company focused on antiviral combination therapies for fibromyalgia and Long-COVID, while later filings under the Dogwood Therapeutics, Inc. name reflect the combined entity following its business Combination with Wex Pharmaceuticals, Inc.
Through this page, users can review Form 8-K current reports that document material events in the company’s transition. For example, an October 2024 press release, referenced in subsequent disclosures, describes the Combination and the change of the corporate name to Dogwood Therapeutics, Inc., along with the shift in Nasdaq trading from the VIRI ticker to DWTX. Later Form 8-K filings filed as Dogwood Therapeutics, Inc. detail matters such as equity incentive plan amendments, annual meeting results and executive compensation adjustments, illustrating the continuity of the registrant under a new name.
Stock Titan enhances these filings with AI-powered summaries that aim to clarify the key points of each document, helping readers quickly understand topics such as corporate governance changes, equity plan share increases or the announcement of quarterly results. Real-time updates from EDGAR mean that new 8-Ks and other forms appear on this page as they are filed, while historical filings remain available for users who want to study the evolution from Virios Therapeutics to Dogwood Therapeutics.
For investors analyzing the former VIRI symbol, this filings archive provides a structured view of how Virios Therapeutics’ antiviral programs and corporate structure were incorporated into Dogwood Therapeutics, Inc., and how the combined company continues to report under the same Commission file number with a new trading symbol.
Dogwood Therapeutics, Inc. (VIRI) filed a Form S-8 to register 108,612 additional shares of common stock for issuance under its Amended and Restated 2020 Equity Incentive Plan. The new shares supplement prior S-8 registrations (Dec 21 2020 and Jun 22 2022) and follow Board authorization on Apr 17 2025 and shareholder approval on Jun 18 2025. Standard incorporation-by-reference, exhibits (legal opinion, auditor consent, plan document) and undertakings are included. The filing is an administrative step to ensure sufficient shares are available for employee equity awards and does not provide new financial results or strategic disclosures.